The Pharmacy Times® Neurology Resource Center is a comprehensive resource for clinical news and expert insights on disorders of the nervous system, including multiple sclerosis, Alzheimer disease, migraine, and Parkinson disease.
June 13th 2024
Anti-amyloid antibody administration decreased plaque volume in clinical trials of patients with early AD, indicating that passive immunotherapies could be a promising treatment for the disease.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Poly...
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Care...
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment
1.5 Credits / Cardiology, Neurology, Rare Diseases
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
FDA Approves Brivaracetam for Treatment of Partial-Onset Seizures in Pediatric Patients
August 30th 2021This is the first time that the intravenous (IV) formulation of brivaracetam will be available for pediatric patients and is the only IV formulation approved for partial-onset seizures and this age group in nearly 7 years.
Read More
Ongoing Developments and Barriers for Treatment of Alzheimer Disease
August 23rd 2021It is the responsibility of the pharmacist to remain informed of all existing and new drugs for the treatment of Alzheimer disease, especially because novel and investigational drugs may target the pathophysiology of the disease.
Read More
FDA Advisory Committee Members Raise Concerns About Aducanumab
July 21st 2021In addition to concerns about the data supporting the FDA approval of aducanumab for patients with Alzheimer disease, FDA advisory committee members raised some unique concerns when they rejected the application in November 2020.
Watch
Expert: Aducanumab Approval Creates Hope, New Opportunities for Patients with Alzheimer Disease
July 16th 2021Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, said there are no other currently available treatments for Alzheimer disease that get to the root of the condition.
Watch